Drysol: Uses, Evidence, and Safety

Drysol is an aluminum chloride treatment, not a permanent fix#

Drysol is a topical aluminum chloride hexahydrate antiperspirant used for hyperhidrosis. A 2008 FDA proprietary-name review—not a current patient label—identifies Drysol as a 20% aluminum chloride solution and records once-daily bedtime application.[3] Current product labeling and a prescriber or pharmacist should govern actual use. The important evidence boundary is that studies of aluminum chloride use different concentrations, vehicles, body sites, and follow-up periods. They support a temporary reduction in sweating for some people; they do not show that one concentration works best everywhere or that aluminum chloride cures hyperhidrosis.

That distinction matters because the search term “Drysol” is often treated as if it names one universal treatment result. The cited clinical literature is narrower: one trial studied feet and another studied palms. Neither was a large placebo-controlled trial of branded Drysol for underarm sweating.[1][2]

What this Drysol review can—and cannot—verify#

Before using a product labeled Drysol: confirm the active ingredient and concentration, the intended body site, the current directions, and the warnings on the dispensed label. This article does not establish current availability or replace that label.

A small randomized trial supports aluminum chloride for sweaty feet#

A randomized half-side trial enrolled 20 volunteers with plantar hyperhidrosis and compared 12.5% with 30% aluminum chloride hexahydrate for 6 weeks. Both concentrations significantly reduced sweat production, and the researchers recommended 12.5% because both were effective.[1] In plain language, the stronger concentration did not establish a clear practical advantage in this small study.

The finding should stay attached to its limits. The trial involved only 20 people, focused on the soles, and lasted 6 weeks. It cannot tell us whether the same concentration comparison applies to underarms or palms, whether benefits persist long term, or which formulation is most tolerable for an individual person.

Palmar evidence shows benefit during treatment, followed by loss of effect#

A separate clinical study evaluated 20% aluminum chloride in 12 people with symptomatic palmar hyperhidrosis. Sweat loss was lower on treated palms during the 4-week treatment period, but the difference was no longer significant after treatment stopped.[2] The useful takeaway is not that 20% is the “right” strength. It is that aluminum chloride can suppress palmar sweating while it is being used, and continued benefit should not be assumed after discontinuation.

This also explains why product instructions and clinician guidance matter. In the palmar study, sweating returned near baseline within 1 week after treatment stopped.[2] A short trial cannot establish years of effectiveness or tolerability.

Irritation and body site can change the tradeoff#

Skin irritation is a meaningful limitation. In the 12-person palmar study, 4 participants developed irritation; 3 continued after it resolved, while 1 withdrew because the irritation was severe.[2] The plantar trial found no tolerability difference between the 2 concentrations and described both as safe, but its 20-person sample cannot rule out clinically important irritation in broader use.[1]

Warnings and directions can differ by formulation and body site. Follow the current label for the specific product rather than transferring directions from another aluminum concentration, vehicle, or antiperspirant. The focused guides to antiperspirant for hands and antiperspirant for feet show why site-specific labeling matters.

Drysol and Qbrexza answer different evidence questions#

Drysol uses aluminum chloride to reduce sweat at the treated skin surface. Qbrexza is a prescription topical anticholinergic approved specifically for primary axillary hyperhidrosis. There is no direct randomized trial in this evidence set that establishes one as universally superior. The relevant questions are body site, prior response, irritation, contraindications, and whether the evidence matches the person being treated.

For the controlled evidence on the prescription cloth, see Qbrexza wipes for underarm sweating. For the broader treatment map, see hyperhidrosis treatment options. The clinical-strength label guide explains why retail terms and prescription status are not one simple strength ladder.

Bottom line#

Evidence supports aluminum chloride as a reasonable topical option for focal hyperhidrosis, but the best-supported claim is modest: small studies show reduced sweating during treatment, with results that depend on body site and formulation.[1][2] Drysol should be understood as one aluminum chloride product, not as proof that a 20% solution is always necessary, always better, or permanently effective.

This article is educational and does not diagnose hyperhidrosis or provide an individualized treatment plan. A clinician or pharmacist can help interpret the product label, distinguish primary from secondary sweating, and assess irritation or contraindications.

References#

1. Streker M, Reuther T, Hagen L, Kerscher M. Hyperhidrosis plantaris: a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115-119. PubMed PMID 21848980

2. Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis: evaporimeter assessment. Int J Dermatol. 1990;29(5):368-370. PubMed PMID 2361796

3. U.S. Food and Drug Administration. 2008 proprietary-name review identifying Drysol as aluminum chloride hexahydrate 20% solution for hyperhidrosis. FDA review PDF